Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > NaturalNano, Inc. Announces Filing of the Form 10K for the Year Ended December 31, 2008

Abstract:
NaturalNano, Inc. (OTC Bulletin Board: NNAN) (FWB: N3N), a developer of extended release technologies and supplier of polymer additives based on naturally occurring nanomaterials, today announced the filing of the Form 10K for the year ended December 31, 2008.

NaturalNano, Inc. Announces Filing of the Form 10K for the Year Ended December 31, 2008

Rochester, NY | Posted on April 16th, 2009

In 2008, The Nano team worked on various development projects with Fortune 500 companies. Fiabila's commercial order, announced April 14, 2009, is a result of our team's development efforts in 2008 and is a validation of our core technology of extended release in consumer products. These technologies are unique to NaturalNano and covered extensively by our patent portfolio. One of our strategic focuses for 2009 is the conversion of our joint development partnership arrangements into commercial orders. We will also be looking for opportunities to license our extensive patent portfolio in product application areas. Our current patent portfolio is displayed on our website (www.naturalnano.com). During 2009, we will be working to strengthen our management and research teams as we continue to seek commercialization opportunities for our unique proprietary technology.

"The recession does not seem to be hindering the high level of company contacts we are continuing to receive," said James Wemett, CEO of NaturalNano. "Companies are paying more attention to our specialized technology of halloysite tubes which are natural occurring, non-toxic, and environmentally friendly and importantly, are not carbon based. There is a growing awareness and interest, across numerous industry applications, of our extensive patent coverage in the extended time release area."

####

About NaturalNano, Inc.
Headquartered in Rochester, NY, NaturalNano, Inc. (OTCBB: NNAN) (FWB: N3N) develops and commercializes products and solutions for extended release attributes for consumer goods as well as polymer additives based on naturally occurring nanomaterials from halloysite. The Company offers its proprietary Pleximer(TM) line of additives for industrial polymers, plastics and composites. NaturalNano holds and licenses more than 25 patents and its applications, as well as proprietary know-how for extraction, classification, and modification of non-toxic and environmentally friendly halloysite natural tubules (HNT).

Cautionary Statement Regarding Forward-Looking Statements: This press release may contain forward-looking statements regarding future events and future performance of NaturalNano that involve risks and uncertainties that could materially affect actual results. This information is qualified in its entirety by cautionary statements and risk factors disclosure contained in certain of NaturalNano’s filings with the Securities and Exchange Commission. The most recent annual reports on Form 10-KSB and quarterly reports on Form 10-QSB filed by NaturalNano provide information about these factors, which may be revised or supplemented in future reports to the SEC on those forms or on Form 8-K. We caution investors not to place undue reliance on forward-looking statements, and we do not undertake any obligation to update or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other such factors that affect the subject of these statements, except where expressly required by law.

For more information, please click here

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024

Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Materials/Metamaterials/Magnetoresistance

New material to make next generation of electronics faster and more efficient With the increase of new technology and artificial intelligence, the demand for efficient and powerful semiconductors continues to grow November 8th, 2024

How surface roughness influences the adhesion of soft materials: Research team discovers universal mechanism that leads to adhesion hysteresis in soft materials March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

Focused ion beam technology: A single tool for a wide range of applications January 12th, 2024

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

Patents/IP/Tech Transfer/Licensing

Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023

Study finds nanomedicine targeting lymph nodes key to triple negative breast cancer treatment: In mice, nanomedicine can remodel the immune microenvironment in lymph node and tumor tissue for long-term remission and lung tumor elimination in this form of metastasized breast cance May 13th, 2022

Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

Financial Reports

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project